Stocks · Health care · Biological Products, (No Diagnostic Substances)

Maze Therapeutics, Inc.

MAZE Clue Score57
United States Fiscal year ends December CIK 0001842295 Results filed 11 Aug 2026

What the insiders did Scheduled selling only

By person

10 insiders · 5 transactions

There is no salary here to measure against. Maze Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Jason Coloma V
Chief Executive Officer
—
$1.04M (4) scheduled
−$1.04M
482,491
0.8686%
$14.98M
−30.7%
Atul Dandekar
Csbo
—
$240.53K (1) scheduled
−$240.53K
32,316
0.0582%
$1.00M
+170.5%
Third Rock Ventures IV, L.P. entity
10% owner
—
—
—
5,424,758
9.77%
$168.45M
+1,643%
Jonathan E Lim
Director
—
—
—
307,956
0.5544%
$9.56M
—
Charles J Homcy
Director
—
—
—
38,535
0.0694%
$1.20M
+7.2%
Amy Bachrodt
SVP, Finance
—
—
—
12,965
0.0233%
$402.60K
0.0%
Phillips Courtney
GC and Corp. Secretary
—
—
—
7,007
0.0126%
$217.59K
—
Harold Bernstein
President, R&D & CMO
—
—
—
0
0.0000%
$0.00
—
Richard H Scheller
Director
—
—
—
0
0.0000%
$0.00
−100.0%
Catherine A. Sohn
Director
—
—
—
0
0.0000%
$0.00
—